Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 150

1.

Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide.

Oerlemans R, Berkers CR, Assaraf YG, Scheffer GL, Peters GJ, Verbrugge SE, Cloos J, Slootstra J, Meloen RH, Shoemaker RH, Dijkmans BAC, Scheper RJ, Ovaa H, Jansen G.

Invest New Drugs. 2018 Oct;36(5):797-809. doi: 10.1007/s10637-018-0569-x. Epub 2018 Feb 14.

2.

Novel Stool-Based Protein Biomarkers for Improved Colorectal Cancer Screening: A Case-Control Study.

Bosch LJW, de Wit M, Pham TV, Coupé VMH, Hiemstra AC, Piersma SR, Oudgenoeg G, Scheffer GL, Mongera S, Sive Droste JT, Oort FA, van Turenhout ST, Larbi IB, Louwagie J, van Criekinge W, van der Hulst RWM, Mulder CJJ, Carvalho B, Fijneman RJA, Jimenez CR, Meijer GA.

Ann Intern Med. 2017 Dec 19;167(12):855-866. doi: 10.7326/M17-1068. Epub 2017 Nov 21.

PMID:
29159365
3.

Sensing of latent EBV infection through exosomal transfer of 5'pppRNA.

Baglio SR, van Eijndhoven MA, Koppers-Lalic D, Berenguer J, Lougheed SM, Gibbs S, Léveillé N, Rinkel RN, Hopmans ES, Swaminathan S, Verkuijlen SA, Scheffer GL, van Kuppeveld FJ, de Gruijl TD, Bultink IE, Jordanova ES, Hackenberg M, Piersma SR, Knol JC, Voskuyl AE, Wurdinger T, Jiménez CR, Middeldorp JM, Pegtel DM.

Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):E587-96. doi: 10.1073/pnas.1518130113. Epub 2016 Jan 14.

4.

Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR.

Verbrugge SE, Al M, Assaraf YG, Kammerer S, Chandrupatla DM, Honeywell R, Musters RP, Giovannetti E, O'Toole T, Scheffer GL, Krige D, de Gruijl TD, Niessen HW, Lems WF, Kramer PA, Scheper RJ, Cloos J, Ossenkoppele GJ, Peters GJ, Jansen G.

Oncotarget. 2016 Feb 2;7(5):5240-57. doi: 10.18632/oncotarget.6169.

5.

Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine.

Adema AD, Floor K, Smid K, Honeywell RJ, Scheffer GL, Jansen G, Peters GJ.

Springerplus. 2014 Dec 13;3:732. doi: 10.1186/2193-1801-3-732. eCollection 2014.

6.

The EGFR pathway regulates BCRP expression in NSCLC cells: role of erlotinib.

Porcelli L, Giovannetti E, Assaraf YG, Jansen G, Scheffer GL, Kathman I, Azzariti A, Paradiso A, Peters GJ.

Curr Drug Targets. 2014;15(14):1322-30.

PMID:
25479544
7.

Control of metazoan heme homeostasis by a conserved multidrug resistance protein.

Korolnek T, Zhang J, Beardsley S, Scheffer GL, Hamza I.

Cell Metab. 2014 Jun 3;19(6):1008-19. doi: 10.1016/j.cmet.2014.03.030. Epub 2014 May 15.

8.

Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors.

Verbrugge SE, Al M, Assaraf YG, Niewerth D, van Meerloo J, Cloos J, van der Veer M, Scheffer GL, Peters GJ, Chan ET, Anderl JL, Kirk CJ, Zweegman S, Dijkmans BA, Lems WF, Scheper RJ, de Gruijl TD, Jansen G.

Exp Hematol Oncol. 2013 Jan 10;2(1):2. doi: 10.1186/2162-3619-2-2.

9.

ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone.

Mourskaia AA, Amir E, Dong Z, Tiedemann K, Cory S, Omeroglu A, Bertos N, Ouellet V, Clemons M, Scheffer GL, Park M, Hallett M, Komarova SV, Siegel PM.

Breast Cancer Res. 2012 Nov 22;14(6):R149. doi: 10.1186/bcr3361.

10.

Expression levels of the ABCG2 multidrug transporter in human erythrocytes correspond to pharmacologically relevant genetic variations.

Kasza I, Várady G, Andrikovics H, Koszarska M, Tordai A, Scheffer GL, Németh A, Szakács G, Sarkadi B.

PLoS One. 2012;7(11):e48423. doi: 10.1371/journal.pone.0048423. Epub 2012 Nov 15.

11.

The multidrug resistance protein breast cancer resistance protein (BCRP) protects adipose-derived stem cells against ischemic damage.

van Dijk A, Naaijkens BA, Jurgens WJ, Oerlemans R, Scheffer GL, Kassies J, Aznou J, Brouwer M, van Rossum AC, Schuurhuis GJ, van Milligen FJ, Niessen HW.

Cell Biol Toxicol. 2012 Oct;28(5):303-15. doi: 10.1007/s10565-012-9225-y. Epub 2012 Jul 17.

PMID:
22801743
12.

Altered arsenic disposition in experimental nonalcoholic fatty liver disease.

Canet MJ, Hardwick RN, Lake AD, Kopplin MJ, Scheffer GL, Klimecki WT, Gandolfi AJ, Cherrington NJ.

Drug Metab Dispos. 2012 Sep;40(9):1817-24. doi: 10.1124/dmd.112.046177. Epub 2012 Jun 14.

13.

Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis.

Verbrugge SE, Assaraf YG, Dijkmans BA, Scheffer GL, Al M, den Uyl D, Oerlemans R, Chan ET, Kirk CJ, Peters GJ, van der Heijden JW, de Gruijl TD, Scheper RJ, Jansen G.

J Pharmacol Exp Ther. 2012 Apr;341(1):174-82. doi: 10.1124/jpet.111.187542. Epub 2012 Jan 10.

PMID:
22235146
14.

Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease.

Hardwick RN, Fisher CD, Canet MJ, Scheffer GL, Cherrington NJ.

Drug Metab Dispos. 2011 Dec;39(12):2395-402. doi: 10.1124/dmd.111.041012. Epub 2011 Aug 30.

15.

Exposure of CD34+ precursors to cytostatic anthraquinone-derivatives induces rapid dendritic cell differentiation: implications for cancer immunotherapy.

van de Ven R, Reurs AW, Wijnands PGJTB, van Wetering S, Kruisbeek AM, Hooijberg E, Scheffer GL, Scheper RJ, de Gruijl TD.

Cancer Immunol Immunother. 2012 Feb;61(2):181-191. doi: 10.1007/s00262-011-1039-x. Epub 2011 Aug 27.

PMID:
21874304
16.

Preferential Langerhans cell differentiation from CD34(+) precursors upon introduction of ABCG2 (BCRP).

van de Ven R, Lindenberg JJ, Reurs AW, Scheper RJ, Scheffer GL, de Gruijl TD.

Immunol Cell Biol. 2012 Feb;90(2):206-15. doi: 10.1038/icb.2011.25. Epub 2011 Mar 29.

PMID:
21445088
17.

High susceptibility of c-KIT+CD34+ precursors to prolonged doxorubicin exposure interferes with Langerhans cell differentiation in a human cell line model.

van de Ven R, Verbrugge SE, Reurs AW, Bontkes HJ, Hooijberg E, Jansen G, Scheper RJ, Scheffer GL, de Gruijl TD.

Cancer Immunol Immunother. 2011 Jul;60(7):943-51. doi: 10.1007/s00262-011-1003-9. Epub 2011 Mar 24.

18.

Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients.

Lemos C, Giovannetti E, Zucali PA, Assaraf YG, Scheffer GL, van der Straaten T, D'Incecco A, Falcone A, Guchelaar HJ, Danesi R, Santoro A, Giaccone G, Tibaldi C, Peters GJ.

Pharmacogenomics. 2011 Feb;12(2):159-70. doi: 10.2217/pgs.10.172.

PMID:
21332310
19.

Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines.

Bierman WF, Scheffer GL, Schoonderwoerd A, Jansen G, van Agtmael MA, Danner SA, Scheper RJ.

J Antimicrob Chemother. 2010 Aug;65(8):1672-80. doi: 10.1093/jac/dkq209. Epub 2010 Jun 15.

PMID:
20551216
20.

Selective transduction of mature DC in human skin and lymph nodes by CD80/CD86-targeted fiber-modified adenovirus-5/3.

van de Ven R, Lindenberg JJ, Oosterhoff D, van den Tol MP, Rosalia RA, Murakami M, Everts M, Scheffer GL, Scheper RJ, de Gruijl TD, Curiel DT.

J Immunother. 2009 Nov-Dec;32(9):895-906. doi: 10.1097/CJI.0b013e3181b56deb.

21.

ABC drug transporters and immunity: novel therapeutic targets in autoimmunity and cancer.

van de Ven R, Oerlemans R, van der Heijden JW, Scheffer GL, de Gruijl TD, Jansen G, Scheper RJ.

J Leukoc Biol. 2009 Nov;86(5):1075-87. doi: 10.1189/jlb.0309147. Epub 2009 Sep 10. Review.

PMID:
19745159
22.

The ABC of dendritic cell development and function.

van de Ven R, Scheffer GL, Scheper RJ, de Gruijl TD.

Trends Immunol. 2009 Sep;30(9):421-9. doi: 10.1016/j.it.2009.06.004. Epub 2009 Aug 21. Review.

PMID:
19699682
23.

Unimpaired immune functions in the absence of Mrp4 (Abcc4).

van de Ven R, de Groot J, Reurs AW, Wijnands PG, van de Wetering K, Schuetz JD, de Gruijl TD, Scheper RJ, Scheffer GL.

Immunol Lett. 2009 Jun 4;124(2):81-7. doi: 10.1016/j.imlet.2009.04.007. Epub 2009 May 3.

PMID:
19406153
24.

Involvement of breast cancer resistance protein expression on rheumatoid arthritis synovial tissue macrophages in resistance to methotrexate and leflunomide.

van der Heijden JW, Oerlemans R, Tak PP, Assaraf YG, Kraan MC, Scheffer GL, van der Laken CJ, Lems WF, Scheper RJ, Dijkmans BA, Jansen G.

Arthritis Rheum. 2009 Mar;60(3):669-77. doi: 10.1002/art.24354.

25.

Cellular folate status modulates the expression of BCRP and MRP multidrug transporters in cancer cell lines from different origins.

Lemos C, Kathmann I, Giovannetti E, Beliën JA, Scheffer GL, Calhau C, Jansen G, Peters GJ.

Mol Cancer Ther. 2009 Mar;8(3):655-64. doi: 10.1158/1535-7163.MCT-08-0768. Epub 2009 Feb 24.

26.

Vault-related resistance to anticancer drugs determined by the expression of the major vault protein LRP.

Izquierdo MA, Scheffer GL, Schroeijers AB, de Jong MC, Scheper RJ.

Cytotechnology. 1998 Sep;27(1-3):137-48. doi: 10.1023/A:1008004502861.

27.

Renal xenobiotic transporters are differentially expressed in mice following cisplatin treatment.

Aleksunes LM, Augustine LM, Scheffer GL, Cherrington NJ, Manautou JE.

Toxicology. 2008 Sep 4;250(2-3):82-8. doi: 10.1016/j.tox.2008.06.009. Epub 2008 Jul 2.

28.

A role for multidrug resistance protein 4 (MRP4; ABCC4) in human dendritic cell migration.

van de Ven R, Scheffer GL, Reurs AW, Lindenberg JJ, Oerlemans R, Jansen G, Gillet JP, Glasgow JN, Pereboev A, Curiel DT, Scheper RJ, de Gruijl TD.

Blood. 2008 Sep 15;112(6):2353-9. doi: 10.1182/blood-2008-03-147850. Epub 2008 Jul 14.

29.

Folate deprivation induces BCRP (ABCG2) expression and mitoxantrone resistance in Caco-2 cells.

Lemos C, Kathmann I, Giovannetti E, Dekker H, Scheffer GL, Calhau C, Jansen G, Peters GJ.

Int J Cancer. 2008 Oct 1;123(7):1712-20. doi: 10.1002/ijc.23677.

30.

Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer.

Ho LL, Kench JG, Handelsman DJ, Scheffer GL, Stricker PD, Grygiel JG, Sutherland RL, Henshall SM, Allen JD, Horvath LG.

Prostate. 2008 Sep 15;68(13):1421-9. doi: 10.1002/pros.20809.

PMID:
18615486
31.

Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.

Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, Scheffer GL, Debipersad K, Vojtekova K, Lemos C, van der Heijden JW, Ylstra B, Peters GJ, Kaspers GL, Dijkmans BA, Scheper RJ, Jansen G.

Blood. 2008 Sep 15;112(6):2489-99. doi: 10.1182/blood-2007-08-104950. Epub 2008 Jun 18.

32.

Hepatic Mrp4 induction following acetaminophen exposure is dependent on Kupffer cell function.

Campion SN, Johnson R, Aleksunes LM, Goedken MJ, van Rooijen N, Scheffer GL, Cherrington NJ, Manautou JE.

Am J Physiol Gastrointest Liver Physiol. 2008 Aug;295(2):G294-304. doi: 10.1152/ajpgi.00541.2007. Epub 2008 Jun 12.

33.

ABCB4 heterozygous gene mutations associated with fibrosing cholestatic liver disease in adults.

Ziol M, Barbu V, Rosmorduc O, Frassati-Biaggi A, Barget N, Hermelin B, Scheffer GL, Bennouna S, Trinchet JC, Beaugrand M, Ganne-Carrié N.

Gastroenterology. 2008 Jul;135(1):131-41. doi: 10.1053/j.gastro.2008.03.044. Epub 2008 Mar 26. Erratum in: Gastroenterology. 2008 Oct;135(4):1429.

PMID:
18482588
34.

Drug-metabolizing enzyme and transporter expression in a mouse model of diabetes and obesity.

Cheng Q, Aleksunes LM, Manautou JE, Cherrington NJ, Scheffer GL, Yamasaki H, Slitt AL.

Mol Pharm. 2008 Jan-Feb;5(1):77-91. doi: 10.1021/mp700114j. Epub 2008 Jan 12.

PMID:
18189363
35.

Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway.

Maher JM, Dieter MZ, Aleksunes LM, Slitt AL, Guo G, Tanaka Y, Scheffer GL, Chan JY, Manautou JE, Chen Y, Dalton TP, Yamamoto M, Klaassen CD.

Hepatology. 2007 Nov;46(5):1597-610.

PMID:
17668877
36.

Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution.

Takenaka K, Morgan JA, Scheffer GL, Adachi M, Stewart CF, Sun D, Leggas M, Ejendal KF, Hrycyna CA, Schuetz JD.

Cancer Res. 2007 Jul 15;67(14):6965-72.

37.

Induction of hepatobiliary efflux transporters in acetaminophen-induced acute liver failure cases.

Barnes SN, Aleksunes LM, Augustine L, Scheffer GL, Goedken MJ, Jakowski AB, Pruimboom-Brees IM, Cherrington NJ, Manautou JE.

Drug Metab Dispos. 2007 Oct;35(10):1963-9. Epub 2007 Jul 12.

PMID:
17627974
38.

Multidrug resistance-associated protein 9 (ABCC12) is present in mouse and boar sperm.

Ono N, Van der Heijden I, Scheffer GL, Van de Wetering K, Van Deemter E, De Haas M, Boerke A, Gadella BM, De Rooij DG, Neefjes JJ, Groothuis TA, Oomen L, Brocks L, Ishikawa T, Borst P.

Biochem J. 2007 Aug 15;406(1):31-40.

39.

cGMP transport by vesicles from human and mouse erythrocytes.

de Wolf CJ, Yamaguchi H, van der Heijden I, Wielinga PR, Hundscheid SL, Ono N, Scheffer GL, de Haas M, Schuetz JD, Wijnholds J, Borst P.

FEBS J. 2007 Jan;274(2):439-50.

40.

Diminished expression of multidrug resistance-associated protein 1 (MRP1) in bronchial epithelium of COPD patients.

van der Deen M, Marks H, Willemse BW, Postma DS, Müller M, Smit EF, Scheffer GL, Scheper RJ, de Vries EG, Timens W.

Virchows Arch. 2006 Dec;449(6):682-8. Epub 2006 Oct 27.

PMID:
17072643
41.

The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models.

Breedveld P, Pluim D, Cipriani G, Dahlhaus F, van Eijndhoven MA, de Wolf CJ, Kuil A, Beijnen JH, Scheffer GL, Jansen G, Borst P, Schellens JH.

Mol Pharmacol. 2007 Jan;71(1):240-9. Epub 2006 Oct 10.

PMID:
17032904
42.

Dendritic cells require multidrug resistance protein 1 (ABCC1) transporter activity for differentiation.

van de Ven R, de Jong MC, Reurs AW, Schoonderwoerd AJ, Jansen G, Hooijberg JH, Scheffer GL, de Gruijl TD, Scheper RJ.

J Immunol. 2006 May 1;176(9):5191-8.

43.

Hormonal regulation of renal multidrug resistance-associated proteins 3 and 4 (Mrp3 and Mrp4) in mice.

Maher JM, Cheng X, Tanaka Y, Scheffer GL, Klaassen CD.

Biochem Pharmacol. 2006 May 14;71(10):1470-8. Epub 2006 Mar 9.

PMID:
16529719
44.

Expression of drug pathway proteins is independent of tumour type.

Zhang W, Shannon WD, Duncan J, Scheffer GL, Scheper RJ, McLeod HL.

J Pathol. 2006 Jun;209(2):213-9.

PMID:
16508919
45.

Induction of hepatic transporters multidrug resistance-associated proteins (Mrp) 3 and 4 by clofibrate is regulated by peroxisome proliferator-activated receptor alpha.

Moffit JS, Aleksunes LM, Maher JM, Scheffer GL, Klaassen CD, Manautou JE.

J Pharmacol Exp Ther. 2006 May;317(2):537-45. Epub 2006 Feb 8.

PMID:
16467456
46.

trans-Stilbene oxide induces expression of genes involved in metabolism and transport in mouse liver via CAR and Nrf2 transcription factors.

Slitt AL, Cherrington NJ, Dieter MZ, Aleksunes LM, Scheffer GL, Huang W, Moore DD, Klaassen CD.

Mol Pharmacol. 2006 May;69(5):1554-63. Epub 2006 Jan 31.

PMID:
16449384
47.

Acquired resistance to chloroquine in human CEM T cells is mediated by multidrug resistance-associated protein 1 and provokes high levels of cross-resistance to glucocorticoids.

Oerlemans R, van der Heijden J, Vink J, Dijkmans BA, Kaspers GJ, Lems WF, Scheffer GL, Ifergan I, Scheper RJ, Cloos J, Assaraf YG, Jansen G.

Arthritis Rheum. 2006 Feb;54(2):557-68.

48.

Vascular colocalization of P-glycoprotein, multidrug-resistance associated protein 1, breast cancer resistance protein and major vault protein in human epileptogenic pathologies.

Sisodiya SM, Martinian L, Scheffer GL, van der Valk P, Scheper RJ, Harding BN, Thom M.

Neuropathol Appl Neurobiol. 2006 Feb;32(1):51-63.

PMID:
16409553
49.

Novel extracellular vesicles mediate an ABCG2-dependent anticancer drug sequestration and resistance.

Ifergan I, Scheffer GL, Assaraf YG.

Cancer Res. 2005 Dec 1;65(23):10952-8.

50.

Vault mobility depends in part on microtubules and vaults can be recruited to the nuclear envelope.

van Zon A, Mossink MH, Houtsmuller AB, Schoester M, Scheffer GL, Scheper RJ, Sonneveld P, Wiemer EA.

Exp Cell Res. 2006 Feb 1;312(3):245-55. Epub 2005 Nov 28.

PMID:
16310186

Supplemental Content

Loading ...
Support Center